Relmada Therapeutics
IPORelmada Therapeutics, Inc.
Public · New York, United States · Founded 2012 · $160.0M raised
- Headquarters
- New York, New York
- Employees
- 11–50
- Founded
- 2012
- Business Model
- B2B
- Website
- relmada.com
- Total Funding
- $160.0M
- Last Round
- $160.0M Private EquityJan 2026
- Rounds
- 1
- Type
- Public
About
Relmada Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel therapies for central nervous system (CNS) disorders, particularly major depressive disorder (MDD). Its lead candidate, esmethadone (REL-1017, d-methadone), is an NMDA receptor channel blocker being developed as a rapid-acting antidepressant. The company also has programs in psilocybin and other CNS indications.
Summary
Relmada Therapeutics is a Biotech company based in New York, United States, founded in 2012. It has raised $160.0M in total across 1 round, most recently a $160.0M Private Equity round in Jan 2026. Investors include Janus Henderson Investors and Braidwell LP.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2026
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...